Antidiabetic And Antilipidemic Matrix Tablet Containing Cordyceps Militaris and Garcinia Cambogia Extracts: A Comprehensive Review of Phytochemistry, Pharmacological Potential and Controlled-Release Formulation Strategies

Diabetes mellitus is a chronic metabolic disease in which persistent elevation of blood glucose results from impaired insulin secretion, insulin resistance, or both. Type 2 diabetes mellitus is commonly accompanied by obesity, dyslipidemia, oxidative stress, chronic low-grade inflammation and progressive cardiovascular risk. The coexistence of hyperglycemia and dyslipidemia requires long-term management and frequently involves more than one pharmacological class. This has stimulated continuing interest in multifunctional natural products that may influence several metabolic pathways.

Medicinal fungi and plants provide chemically diverse compounds with potential metabolic activity. Cordyceps militaris has attracted pharmaceutical and nutraceutical interest because of its nucleosides, polysaccharides, sterols, pigments and other secondary metabolites. Recent reviews describe C. militaris polysaccharides as having hypoglycemic, hypolipidemic, antioxidant, anti-inflammatory and anti-atherosclerotic potential.¹,² Cordycepin, a characteristic nucleoside, has also been investigated for effects on AMPK signaling, lipid metabolism, adipogenesis and inflammation.³

Garcinia cambogia (synonym/commonly used name for Garcinia gummi-gutta) is a tropical fruit whose rind contains hydroxycitric acid. HCA is a competitive inhibitor of ATP-citrate lyase, an enzyme connecting citrate metabolism with cytosolic acetyl-CoA production and lipogenesis.⁴ The mechanism provides a rationale for investigating HCA-containing extracts in lipid-management strategies. Nevertheless, clinical outcomes are heterogeneous and should not be overstated.

A 2024 systematic review and meta-analysis of 14 randomized controlled trials involving 623 adults reported that G. cambogia significantly reduced total cholesterol and triglycerides and increased HDL cholesterol, while LDL cholesterol was not significantly changed.⁵ In contrast, a separate meta-analysis of randomized trials did not demonstrate a significant overall effect of G. cambogia on fasting blood glucose or insulin.⁶ These findings suggest that the most defensible role of G. cambogia in a proposed combined formulation is as a lipid-metabolism-focused ingredient rather than a proven antidiabetic medicine.

The pharmaceutical dosage form can strongly influence the performance of herbal extracts. Immediate-release powders or tablets may expose the gastrointestinal tract to rapidly changing concentrations and may provide limited control over release of chemically diverse constituents. Matrix tablets, particularly hydrophilic polymer matrices containing HPMC, can hydrate after administration and form a gel layer that controls diffusion and erosion.⁷ A standardized dual-extract matrix tablet may therefore provide a rational platform for investigating prolonged oral delivery.

The objective of this review is to critically summarize the scientific basis for combining C. militaris and G. cambogia extracts in an antidiabetic and antilipidemic matrix tablet, with emphasis on phytochemistry, mechanisms of action, standardization, formulation design, evaluation, safety and future research needs.

 

 

Figure 1. Conceptual rationale for combining standardized C. militaris and G. cambogia extracts in a controlled-release matrix tablet.

 

 

Figure 2. Proposed antidiabetic mechanisms associated with C. militaris constituents.

 

 

Figure 3. Simplified biochemical pathway illustrating HCA-mediated inhibition of ATP-citrate lyase.

 

 

Figure 4. Generalized mechanism of controlled release from a hydrophilic HPMC matrix tablet.

 

 

Figure 5. Conceptual—not experimental—release profile for an optimized controlled-release matrix tablet.

PROPOSED PHARMACOLOGICAL EVALUATION

The optimized formulation should first be evaluated using in-vitro assays. α-Amylase and α-glucosidase inhibition can provide preliminary evidence of carbohydrate-digestive enzyme effects, while cellular glucose uptake assays may provide information on insulin-independent or insulin-sensitizing pathways. Antioxidant assays can be included as supportive rather than definitive evidence of antidiabetic efficacy.

For lipid-related evaluation, cellular lipid-accumulation assays, adipocyte differentiation models and appropriate enzyme or molecular assays can be used. The combination should be compared with each extract alone to determine whether the effect is additive, synergistic or simply attributable to one component.

If preclinical evidence is adequate, an appropriately powered animal study can compare normal control, disease control, standard treatment, each extract, the extract combination and the optimized matrix tablet. Blood glucose, oral glucose tolerance, insulin sensitivity, total cholesterol, triglycerides, HDL, LDL, liver enzymes, oxidative-stress markers and histopathology may be assessed.

SAFETY CONSIDERATIONS

Natural origin does not guarantee safety. Safety assessment should include acute and repeated-dose toxicity, hematological and biochemical investigations, liver and kidney function, histopathology and, where justified, genotoxicity. Particular attention is warranted for Garcinia products because reports of liver injury have been associated with some preparations.¹³

Potential herb–drug interactions are also important because individuals with diabetes and dyslipidemia may receive metformin, sulfonylureas, insulin, statins, antihypertensive agents and other chronic medicines. The proposed formulation should not be recommended as a substitute for established therapy without clinical evidence.

RESEARCH GAPS

The most important limitation in the current literature is the absence of convincing direct evidence for a combined C. militaris–Garcinia matrix tablet. Evidence exists separately for C. militaris metabolic activity and for selected effects of HCA-containing Garcinia preparations, but these findings cannot automatically be extrapolated to a combined dosage form.

Additional gaps include variability in fungal strain and cultivation conditions, differences in extract preparation, inconsistent HCA standardization, limited human pharmacokinetic data, uncertainty about the optimal extract ratio and lack of long-term clinical trials. Controlled-release formulation introduces another variable because polymer hydration may alter the exposure of chemically diverse constituents.

FUTURE PERSPECTIVES

Future work should integrate pharmacognosy, phytochemistry, pharmaceutical technology and metabolic pharmacology. Standardized raw materials should be produced under controlled conditions and characterized using validated chromatographic methods. Design-of-experiments approaches can optimize extract ratio and polymer concentration. In-vitro dissolution should quantify multiple markers, and pharmacokinetic studies should compare immediate-release and matrix formulations.

If the optimized formulation demonstrates reproducible physicochemical quality and pharmacological activity, subsequent studies should address chronic toxicity, herb–drug interactions and well-designed clinical trials. Clinical studies should use validated metabolic endpoints rather than surrogate claims alone. The final therapeutic positioning should be determined by the strength of clinical evidence.

METABOLIC BASIS OF DIABETES AND DYSLIPIDEMIA

Type 2 diabetes and dyslipidemia are biologically interconnected rather than isolated abnormalities. Insulin resistance increases hepatic glucose production and alters adipose-tissue lipolysis, resulting in an increased delivery of free fatty acids to the liver. Hepatic lipid synthesis and very-low-density lipoprotein production may consequently increase, while HDL metabolism and LDL particle characteristics become unfavorable. This metabolic pattern is commonly described as diabetic dyslipidemia and is strongly associated with cardiovascular risk. A formulation intended to address both glucose and lipid metabolism therefore has a logical pharmacological basis, provided that each component contributes measurable activity.

Oxidative stress and chronic low-grade inflammation further connect these abnormalities. Excess glucose and fatty acids can increase reactive oxygen species, activate inflammatory transcription factors and impair insulin signaling. The AMPK pathway is particularly relevant because it functions as a cellular energy sensor and coordinates glucose uptake, fatty-acid oxidation and inhibition of energy-consuming anabolic pathways. This provides one reason why AMPK-modulating natural products have been investigated for metabolic disorders.

The formulation concept discussed in this review should therefore be understood as a multi-target approach: C. militaris may provide constituents acting on energy sensing, inflammation, oxidative stress and carbohydrate/lipid metabolism, while HCA from Garcinia provides a more specific biochemical target related to ATP-citrate lyase and lipogenesis.

PHARMACOLOGICAL SIGNIFICANCE OF CORDYCEPIN

Cordycepin (3'-deoxyadenosine) is one of the best-known characteristic metabolites of *C. militaris*. Its structural relationship with adenosine has stimulated extensive investigation of its cellular actions. Reported activities include modulation of AMP/AMPK-related signaling, inhibition of inflammatory pathways, effects on lipid metabolism and regulation of cell proliferation. The precise response depends on dose, cell type, exposure time and experimental system.

From a formulation perspective, cordycepin is an attractive marker because it can be quantified chromatographically and can provide a chemically defined quality-control parameter for a complex fungal extract. Nevertheless, cordycepin alone should not be treated as synonymous with the biological activity of the whole extract because polysaccharides, sterols and other metabolites may contribute to the overall effect.

Recent adipocyte research is particularly relevant to the proposed antilipidemic objective. *C. militaris* extract and cordycepin reduced lipid-droplet accumulation in cultured 3T3-L1 cells and increased hormone-sensitive lipase activity. In a diabetic-obese mouse model, treatment reduced LDL/VLDL-related parameters and oxidative-stress markers. These observations support further investigation but remain preclinical and cannot be directly converted into a human therapeutic dose.

ROLE OF CORDYCEPS POLYSACCHARIDES

Polysaccharides from C. militaris are structurally heterogeneous. Their molecular weight, monosaccharide composition, degree of branching and protein association can vary with strain and extraction conditions. Such variation is important because different polysaccharide fractions may display different biological effects.

Hypoglycemic mechanisms proposed for C. militaris polysaccharides include inhibition of carbohydrate-digesting enzymes, improvement of insulin sensitivity, reduction of oxidative stress and modulation of inflammatory signaling. Some studies have also identified effects on gut microbiota and intestinal-barrier pathways. These findings are important because the metabolic activity of high-molecular-weight polysaccharides may not depend on systemic absorption in the same way as small molecules.

For pharmaceutical standardization, total polysaccharide content alone may be insufficient. A robust quality system should combine a quantitative marker such as cordycepin with a validated total-polysaccharide assay and, where feasible, a chromatographic fingerprint. This approach can reduce the risk of treating chemically different fungal extracts as equivalent.

ROLE OF HYDROXYCITRIC ACID

Hydroxycitric acid is the principal metabolic marker associated with Garcinia fruit rind. The mechanistic interest of HCA derives mainly from ATP-citrate lyase inhibition. By limiting the conversion of citrate into acetyl-CoA, HCA may reduce substrate availability for fatty-acid synthesis. The magnitude of the biological effect, however, depends on dose, exposure, formulation, food intake, metabolic status and the actual HCA content of the product.

An important formulation consideration is that HCA is a small organic acid, whereas C. militaris polysaccharides are much larger and chemically heterogeneous. Their dissolution and diffusion through an HPMC matrix may therefore differ substantially. A formulation optimized only for one marker may produce inadequate control of the other. Simultaneous dissolution analysis of HCA and cordycepin is consequently recommended during development.

EXTRACTION TECHNOLOGY AND QUALITY STANDARDIZATION

Extraction is a critical determinant of the final biological profile. Conventional maceration, percolation and reflux extraction are simple but may require long processing times and large solvent volumes. Ultrasound-assisted extraction, microwave-assisted extraction, enzyme-assisted extraction and optimized aqueous extraction can improve recovery of selected constituents. The method should be selected according to the desired marker rather than maximizing crude extract yield alone.

For C. militaris, cultivation conditions should be recorded because strain, substrate composition, illumination, temperature, pH and fermentation duration can influence cordycepin, polysaccharide and carotenoid production. A pharmaceutical specification should therefore include authenticated strain/source information, identity testing, moisture, microbial quality, contaminant limits and marker assays.

For Garcinia, authentication of the fruit material and quantitative determination of HCA are essential. The extraction procedure should be validated for recovery, repeatability, specificity and stability. Chromatographic fingerprints can complement the HCA assay and help identify adulteration or major compositional changes.

Good Agricultural and Collection Practice principles, appropriate fungal-cultivation controls, validated extraction procedures and Good Manufacturing Practice are important for reproducible herbal products. A matrix tablet cannot compensate for poor-quality starting material; formulation quality begins with raw-material quality.

ANALYTICAL STANDARDIZATION OF THE PROPOSED TABLET

A dual-marker analytical strategy is recommended. Cordycepin may serve as the principal low-molecular-weight marker for C. militaris, while HCA may serve as the principal marker for Garcinia. Total polysaccharide content can be used as an additional quality attribute for the fungal extract. HPLC, HPTLC or LC-MS methods may be selected depending on the required sensitivity and laboratory resources.

Method validation should address specificity, linearity, accuracy, precision, range, limit of detection, limit of quantification, robustness and solution stability where applicable. The analytical method should be able to distinguish the markers from excipient peaks and degradation products.

FORMULATION VARIABLES AFFECTING MATRIX RELEASE

The release performance of an HPMC matrix is controlled by polymer viscosity grade, polymer concentration, tablet porosity, compression force, active dose, particle size and dissolution conditions. Higher polymer concentration generally increases the diffusion path and gel strength and may prolong release. However, excessive polymer can produce incomplete release or a very slow initial phase.

Compression force is also important. Increasing compression can reduce porosity and slow penetration of dissolution medium, whereas insufficient compression may produce fragile tablets and variable release. Lubrication time should be controlled because excessive hydrophobic lubricant coating can adversely influence wetting and dissolution.

Because the formulation contains two extracts, a design-of-experiments approach is preferable to changing one factor at a time. Candidate independent variables may include HPMC concentration, HPMC viscosity grade, extract ratio, diluent ratio and compression force. Responses can include hardness, friability, swelling, assay, HCA release at selected times, cordycepin release at selected times and similarity between dissolution profiles.

QUALITY-BY-DESIGN FRAMEWORK

A quality-by-design approach begins with a quality target product profile. For the proposed formulation, the target could be an immediate oral matrix tablet containing standardized amounts of HCA and cordycepin, acceptable mechanical strength, controlled release over a predefined period and adequate stability. Risk assessment can then identify the material and process variables most likely to affect critical quality attributes.

A response-surface design may be used to determine an optimum region rather than a single formulation point. The optimized formulation should be confirmed by preparing independent batches and comparing observed responses with model predictions. Such confirmation improves the scientific robustness of formulation development and provides a clearer path toward scale-up.

BIOPHARMACEUTIC CONSIDERATIONS

Controlled release does not automatically increase bioavailability. If a marker has poor permeability or undergoes extensive metabolism, slowing its release may not improve systemic exposure. Conversely, controlled release can reduce high local concentrations and may improve exposure consistency. Therefore, dissolution data should ultimately be linked to pharmacokinetic information.

The proposed formulation also contains constituents with potentially different absorption pathways. Cordycepin is a small nucleoside-related molecule, HCA is a small organic acid, and polysaccharides may exert local intestinal or microbiota-related effects. A single release profile may therefore not fully describe the biological behavior of the complete extract.

PROPOSED IN-VITRO AND IN-VIVO STUDY DESIGN

An appropriate development program should compare the individual extracts with the combination. In-vitro experiments may include α-amylase and α-glucosidase inhibition, glucose-uptake assays, antioxidant assays and lipid-accumulation models. The combination should be tested over a concentration matrix so that additive, synergistic or antagonistic interactions can be distinguished.

In animal studies, a metabolically relevant model such as high-fat diet plus low-dose streptozotocin may be considered. Groups should include normal control, diabetic control, standard treatment, *C. militaris*, *Garcinia*, combination, and optimized matrix tablet. Endpoints should include fasting glucose, oral glucose tolerance, insulin resistance, triglycerides, total cholesterol, HDL, LDL, liver enzymes, oxidative-stress markers and histopathology.

Pharmacokinetic studies should compare the immediate-release extract combination with the optimized matrix tablet. Key parameters include maximum concentration, time to maximum concentration, exposure and apparent elimination behavior of measurable markers. For polysaccharides, systemic pharmacokinetics may not be appropriate, and local intestinal effects should also be considered.

STABILITY AND PACKAGING

Stability testing should evaluate marker content, dissolution, physical appearance, hardness, moisture and microbial quality over time. Because both extracts may contain oxidation-sensitive constituents, protection from excessive humidity, light and oxygen may be required. Packaging should be selected after moisture-sensitivity and compatibility studies.

Accelerated and long-term stability studies should follow the applicable regulatory framework used for the intended market. Any change in HCA or cordycepin content should be correlated with dissolution and physical changes so that a meaningful shelf-life specification can be established.

REGULATORY AND TRANSLATIONAL CONSIDERATIONS

The regulatory status of a product containing standardized fungal and botanical extracts depends on its intended claims, composition, manufacturing process and jurisdiction. A product positioned as a food or nutraceutical may be subject to different requirements from a product making therapeutic claims. The evidence required for antidiabetic or antilipidemic therapeutic claims is substantially stronger than evidence supporting general nutritional use.

For pharmaceutical development, authentication, standardization, contaminant control, stability, validated analytical methods and reproducible manufacturing are essential. If clinical therapeutic claims are intended, controlled clinical trials should establish efficacy and safety. The existence of preclinical literature should not be interpreted as sufficient evidence for human treatment.

LIMITATIONS OF THE CURRENT EVIDENCE

Several limitations should be considered when interpreting the literature. First, a large proportion of C. militaris metabolic evidence is preclinical. Second, the chemical composition of fungal preparations varies with strain and cultivation. Third, Garcinia clinical trials are heterogeneous in dose, duration and product standardization. Fourth, the proposed combination has not been adequately studied as a matrix tablet. Fifth, long-term safety and herb–drug interactions require further evaluation.Accordingly, the present review supports a research hypothesis rather than a therapeutic conclusion. The proposed matrix tablet should be investigated through a staged program of authentication, extraction, standardization, formulation optimization, dissolution testing, pharmacological evaluation, safety assessment and clinical translation.Table 9. Proposed staged development pathway for the dual-extract matrix tablet.

CONCLUSION

The combination of Cordyceps militaris and Garcinia cambogia represents a scientifically plausible research concept for a multifunctional antidiabetic and antilipidemic matrix tablet. C. militaris provides cordycepin and polysaccharides with preclinical evidence for effects on glucose metabolism, insulin sensitivity, lipid metabolism, inflammation and oxidative stress. Garcinia provides HCA, a mechanistically relevant inhibitor of ATP-citrate lyase with clinical evidence suggesting modest improvements in selected lipid parameters but inconsistent glycemic effects.

A hydrophilic HPMC matrix can provide a practical platform for prolonged oral delivery of standardized extracts. However, the proposed combined tablet should be regarded as an experimental formulation rather than a clinically established product. Direct comparison of individual extracts, the combination and the optimized matrix formulation is essential to determine whether meaningful additive or synergistic effects occur. Standardization, controlled release, pharmacological validation, safety testing and clinical investigation will be necessary before therapeutic claims can be made.

ACKNOWLEDGEMENT

The authors acknowledge the academic and institutional support provided for preparation of this review.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Raslamol K,Dinesh Pappan D. Unveling the ancient secret;investigating the identity of cordyceps sinesis. Mritha sanjeevani. 2025:12(2):2945-2950.
2. Wu N, Ge X, Yin X, Yang L, Chen L, Shao R, Xu W. A review on polysaccharide biosynthesis in Cordyceps militaris. Int J Biol Macromol. 2024;260(Pt 1):129336.
3. Yue K, Ye M, Zhou Z, Sun W, Lin X. The genus Cordyceps: a chemical and pharmacological review. J Pharm Pharmacol. 2013;65(4):474-493.
4. Mazzio EA, Soliman KF. Inhibition of the arachidonic acid cascade by Garcinia cambogia extract and hydroxycitric acid. J Agric Food Chem. 2002;50:10-22.
5. Amini MR, Rasaei N, Jalalzadeh M, et al. The effects of Garcinia cambogia (hydroxycitric acid) on lipid profile: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2024;38(2):1028-1043.
6. The effects of Garcinia cambogia on glycaemic control and liver enzymes in adults: a systematic review and meta-analysis of randomized controlled trials. 2025.
7. Colombo GL, et al. Oral controlled-release matrix tablets: formulation and drug-release mechanisms. Drug Dev Ind Pharm. 2013;39:1-12.
8. Park HJ. Influence of culture conditions on bioactive compounds in Cordyceps militaris: a comprehensive review. Foods. 2025;14(19):3408.
9. Meshram V, Jadhav SK, Chandrawanshi NK. Strain improvement of Cordyceps militaris for optimized bioactive metabolite biosynthesis: current progress and prospective approaches. Antonie Van Leeuwenhoek. 2025;118(11):162.
10. Liu Y, et al. Cordyceps militaris polysaccharides alleviate diabetic symptoms by regulating gut microbiota against TLR4/NF-kB pathway. Int J Biol Macromol. 2023.
11. Cordyceps militaris polysaccharides: structural characteristics, biological activities and pharmaceutical prospects. Front Nutr. 2022;9:898674.
12. Effect of Cordyceps militaris extract containing cordycepin on the adipogenesis and lipolysis of adipocytes. FEBS Open Bio. 2024.
13. National Center for Complementary and Integrative Health. Garcinia cambogia. NCCIH. Updated information accessed 2026.
14. Márquez F, Babio N, Bulló M, Salas-Salvadó J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr. 2012;52(7):585-594.
15. Clouatre DL, Preuss HG. Hydroxycitric acid: a comprehensive review of its pharmacology and toxicology. Evid Based Complement Alternat Med. 2013;2013:1-12.
16. Yamada T, Hida S, Yamada Y. Chemistry, physiological properties and applications of Cordyceps militaris and its constituents. Food Chem. 2014.
17. Cordyceps polysaccharides: a review of their metabolic and immunomodulatory activities. Molecules. 2024.
18. Natural polymers in the formulation of hydrophilic matrix tablets. Int J Pharm. 2006.
19. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.
20. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.
21. Meshram V, Jadhav SK, Chandrawanshi NK. Strain improvement of Cordyceps militaris for optimized bioactive metabolite biosynthesis: current progress and prospective approaches. Antonie Van Leeuwenhoek. 2025;118(11):162.
22. Park HJ. Influence of culture conditions on bioactive compounds in Cordyceps militaris: a comprehensive review. Foods. 2025;14(19):3408.
23. Amini MR, Salavatizadeh M, Kazeminejad S, et al. The effects of Garcinia cambogia (hydroxycitric acid) on serum leptin concentrations: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2024;84:103060.
24. Márquez F, Babio N, Bulló M, Salas-Salvadó J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr. 2012;52(7):585-594.
25. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.
26. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.